Sponsored by
This article shows that most GBMs overexpress IL-13Rα2 and that this may be involved in making the tumor invasive, proliferation and angiogenesis. There are a few experimental treatments that target this marker. ICT-107 was a vaccine that showed remarkable results in a few subgroups of patients but "failed" their pivotal trial and is no longer in development. GB-13 is in preclinical testing and hopefully will get into clinical trials soon..